{"id":"ricover-scheme-rituximab","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Infusion reactions"},{"rate":"25-40","effect":"Neutropenia"},{"rate":"15-25","effect":"Anemia"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"15-25","effect":"Infection"},{"rate":"20-30","effect":"Nausea/vomiting"},{"rate":"20-30","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. Upon binding, it triggers B cell destruction through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The R-CHOP/Ricover scheme combines rituximab with chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) to enhance anti-tumor efficacy in B-cell malignancies.","oneSentence":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduced antibody production in lymphoma and autoimmune conditions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:08.304Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma (as part of R-CHOP/Ricover chemotherapy regimen)"},{"name":"Diffuse large B-cell lymphoma (DLBCL)"}]},"trialDetails":[{"nctId":"NCT01478542","phase":"PHASE3","title":"OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2011-11","conditions":"CD20+ Aggressive B-Cell Lymphoma","enrollment":1152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33045,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ricover-scheme rituximab","genericName":"Ricover-scheme rituximab","companyName":"Universität des Saarlandes","companyId":"universit-t-des-saarlandes","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduced antibody production in lymphoma and autoimmune conditions. Used for B-cell non-Hodgkin lymphoma (as part of R-CHOP/Ricover chemotherapy regimen), Diffuse large B-cell lymphoma (DLBCL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}